200 related articles for article (PubMed ID: 37863403)
1. Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors.
Maiorano BA; Conteduca V; Catalano M; Antonuzzo L; Maiello E; De Giorgi U; Roviello G
Crit Rev Oncol Hematol; 2023 Dec; 192():104157. PubMed ID: 37863403
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
3. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
Xia M; Guo Z; Hu Z
Biomolecules; 2021 May; 11(5):. PubMed ID: 34066020
[TBL] [Abstract][Full Text] [Related]
4. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
5. PARP Inhibitors in Prostate Cancer.
Ramakrishnan Geethakumari P; Schiewer MJ; Knudsen KE; Kelly WK
Curr Treat Options Oncol; 2017 Jun; 18(6):37. PubMed ID: 28540598
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
Brönimann S; Lemberger U; Bruchbacher A; Shariat SF; Hassler MR
Curr Opin Urol; 2020 Jul; 30(4):519-526. PubMed ID: 32427631
[TBL] [Abstract][Full Text] [Related]
7. New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy.
Ceci F; Airò Farulla LS; Bonatto E; Evangelista L; Aliprandi M; Cecchi LG; Mattana F; Bertocchi A; DE Vincenzo F; Perrino M; Cordua N; Borea F; Zucali PA
Q J Nucl Med Mol Imaging; 2024 Jun; 68(2):101-115. PubMed ID: 38860274
[TBL] [Abstract][Full Text] [Related]
8. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
9. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
[TBL] [Abstract][Full Text] [Related]
10. Precision Medicine in Castration-Resistant Prostate Cancer: Advances, Challenges, and the Landscape of PARPi Therapy-A Narrative Review.
Dimitrov G; Mangaldzhiev R; Slavov C; Popov E
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396858
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
Sigorski D; Iżycka-Świeszewska E; Bodnar L
Target Oncol; 2020 Dec; 15(6):709-722. PubMed ID: 33044685
[TBL] [Abstract][Full Text] [Related]
12. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
13. PARP Inhibitors in Ovarian Cancer.
Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
[TBL] [Abstract][Full Text] [Related]
14. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Adashek JJ; Jain RK; Zhang J
Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Jang A; Sartor O; Barata PC; Paller CJ
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233320
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
Ratta R; Guida A; Scotté F; Neuzillet Y; Teillet AB; Lebret T; Beuzeboc P
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):549-560. PubMed ID: 32367009
[TBL] [Abstract][Full Text] [Related]
17. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
18. PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape.
Al-Akhras A; Hage Chehade C; Narang A; Swami U
Life (Basel); 2024 Jan; 14(2):. PubMed ID: 38398706
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
20. DNA Repair and Prostate Cancer: A Field Ripe for Harvest.
Bryce AH; Sartor O; de Bono J
Eur Urol; 2020 Oct; 78(4):486-488. PubMed ID: 32636098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
